恒瑞医药的新爆点

药渡
Aug 17

近期,恒瑞医药又拿下一笔BD大单:将PDE3/4抑制剂HRS-9821的海外权益以及11个创新项目的独家选择权授权给葛兰素史克(GSK),将有望获得潜在总交易额125亿美元(其中首付款5亿美元)。这一利好消息,让恒瑞医药A股涨停,总市值成功突破4000亿元大关,H股的总市值更是一度超过5600亿港元。此次BD合作,再次验证了恒瑞在免疫和呼吸系统疾病领域的研发实力。更重要的是,恒瑞在这一领域还藏着...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10